Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages and can eventually destroy the bile ducts of the liver. Researchers ...

which is now called primary biliary cholangitis (PBC), are chronic cholestatic liver diseases, but they differ in their causes, affected bile ducts, and associations. Over time, the bile ducts ...

Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...

For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications ...

At present, the gold standard for the diagnosis of recurrent PBC is a liver biopsy demonstrating the characteristic histologic features, with the exclusion of other entities that can lead to graft ...

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade. With the FDA approval of Gilead's ...

The analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC). Interim results from the ...

There isn’t a cure for PBC, but the right treatment plan can slow its progress and boost your quality of life as you live with it.

Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat patients with the rare liver disease primary biliary cholangitis (PBC). The ...